-Advertisement-
-Advertisement-
Journal Scan
Ganaxolone reduces frequency of CDKL5 deficiency disorder-associated seizures
Patients with CDKL5 deficiency disorder (CDD) had less frequent CDD-associated seizures when treated with an investigational neuroactive steroid, Ganaxolone, compared with placebo, according to the results of a phase 3 trial. In the double-blind phase of this randomized, placebo-controlled, 101 patients between the ages of 2-21 years with a pathogenic...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Contact
© 2024 Med Journal 360® is a trademark of International Healthcare Media, LLC. All rights Reserved